Adams Diversified Equity Fund Inc. reduced its position in AbbVie Inc. by 31.1% in the first quarter, selling 58,300 shares to hold a remaining stake of 129,400 shares valued at $28.1 million. While this major fund decreased its exposure, several smaller institutional investors including Chelsea...
في 23 يونيو 2026، أعلنت شركة AbbVie (ABBV) عن موافقات تنظيمية هامة تشمل الموافقة الكندية على عقار Boey لتحسين خطوط الوجه لدى البالغين، وهو أول نوع مصلي E معتمد من التوكسين العصبي البوتولينوم لهذا الغرض. كما وافقت المفوضية الأوروبية على عقار Maviret لعلاج عدوى فيروس...
Apella Capital LLC significantly increased its stake in AbbVie Inc. (NYSE: ABBV) by 97.9% in the first quarter, purchasing an additional 10,041 shares to hold a total of 20,298 shares valued at $4.23 million. Several other institutional investors, including Thoma Capital Management LLC and Consilium...
AbbVie (NYSE: ABBV) recently presented landmark nine-year follow-up data from the Phase 3 CLL14 trial at the European Hematology Association 2026 meeting. The results confirm that a one-year fixed-duration venetoclax combination therapy provides a median of approximately eight years off treatment before requiring further intervention....
AbbVie (ABBV) has successfully transitioned from its Humira patent cliff by scaling its Skyrizi and Rinvoq immunology franchises, driving a 28% stock gain over the past year. The company recently announced an all-cash acquisition of clinical-stage biotech Apogee Therapeutics for nearly $11 billion to bolster...
Claris Financial LLC increased its investment in AbbVie Inc. (NYSE: ABBV) during the fourth quarter by purchasing 7,840 shares valued at approximately $1.79 million. This acquisition represents about 1% of Claris's portfolio, making it the firm's 18th largest holding. Several other institutional investors also adjusted...
AbbVie Inc. (NYSE: ABBV) presented new Phase 3 data from the CLL14 trial at the European Hematology Association 2026 Congress in Stockholm, showing that a fixed-duration combination of venetoclax and obinutuzumab significantly improved progression-free survival compared to chlorambucil plus obinutuzumab in previously untreated chronic lymphocytic...
AbbVie (NYSE: ABBV) is described as an underrated growth story with CEO Robert A. Michael reporting that the company exceeded expectations in Q1 2026. Despite shares trading at $221.59, down 1.43% year-to-date, revenue accelerated by 12.4% year-over-year. Immunology revenue specifically hit $7.29 billion, driven by...
AbbVie Inc. (ABBV) has successfully transitioned its revenue base, with Skyrizi and Rinvoq now exceeding the peak sales of its former blockbuster drug, Humira. The company is currently trading at a forward P/E ratio of 14.8x, which sits below the average for pharmaceutical peers. Management...
CNBC's 'Final Trades' segment highlighted four specific investment picks from various market professionals, with AbbVie (NYSE: ABBV) selected by Bill Baruch, founder and CIO of Blue Line Capital and Blue Creek Capital Management. The article notes that AbbVie shares rose 1% to settle at $227.23...
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...
AbbVie announced on June 8, 2026, that it will present new clinical data across its blood cancer portfolio at the European Hematology Association (EHA) 2026 Congress in Stockholm. The presentation includes six oral and multiple poster sessions highlighting advancements in multiple myeloma, follicular lymphoma, chronic...
AbbVie Inc. (NYSE: ABBV) is a global biopharmaceutical powerhouse with a market capitalization exceeding $400 billion, founded in 2013 as a spinoff from Abbott Laboratories. The company focuses on innovative treatments for immunology, oncology, virology, and neurology, anchored by its top-selling drug Humira and newer...
AbbVie Inc. (NYSE: ABBV) has received regulatory approvals for two of its key products in the European Union, marking significant milestones for its pipeline. On June 2, the European Commission approved AQUIPTA for the acute treatment of migraine in adults with or without aura. This...
AbbVie received European Commission approval for Aquipta (atogepant) as an acute treatment for migraine in adults with or without aura, marking its second approved indication in the EU. The decision was based on data from the pivotal phase III ECLIPSE study, which demonstrated that Aquipta...
The European Commission has granted approval for AbbVie's Aquipta (atogepant) to treat acute migraine attacks in adults with or without aura, marking the second indication for the drug within the European Union. This new approval expands on its existing status as a once-daily preventive treatment...
AbbVie has received approval from the European Commission for AQUIPTA (atogepant) as an acute treatment for migraine in adults, marking a significant expansion of its migraine therapy portfolio in the European Union. The drug is indicated for the acute treatment of migraine attacks in adults...
AbbVie and Pfizer are compared as healthcare investment options for 2026, with AbbVie generating approximately $61.2 billion in FY 2025 revenue and net income of $4.2 billion, while Pfizer reported $62.6 billion in revenue and $7.8 billion in net income for the same period. AbbVie...
Dr. Noah Merin, an assistant professor of medicine at Cedars-Sinai Medical Center, discusses the evolving treatment landscape for acute myeloid leukemia (AML), highlighting a shift from traditional high-intensity chemotherapy to more targeted approaches based on genomic information. He references a pivotal 2016 study published in...
AbbVie has announced the advancement of its experimental autoimmune drug candidate, ABBV-519, into a first-in-human Phase 1 clinical trial. The study is designed as an open-label, non-randomized, single ascending dose evaluation to assess the pharmacokinetics, pharmacodynamics, and safety profile of the drug in adults suffering...
